2024 ICD-10-CM Diagnosis Code T50.905

Adverse effect of unspecified drugs, medicaments and biological substances

ICD-10-CM Code:
T50.905
ICD-10 Code for:
Adverse effect of unsp drug/meds/biol subst
Is Billable?
Not Valid for Submission
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances
        (T50)

T50.905 is a non-specific and non-billable diagnosis code code, consider using a code with a higher level of specificity for a diagnosis of adverse effect of unspecified drugs, medicaments and biological substances. The code is not specific and is NOT valid for the year 2024 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.

Unspecified diagnosis codes like T50.905 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.

Specific Coding Applicable to Adverse effect of unsp drug/meds/biol subst

Non-specific codes like T50.905 require more digits to indicate the appropriate level of specificity. Consider using any of the following ICD-10-CM codes with a higher level of specificity when coding for adverse effect of unsp drug/meds/biol subst:

  • Use T50.905A for initial encounter - BILLABLE CODE

  • Use T50.905D for subsequent encounter - BILLABLE CODE

  • Use T50.905S for sequela - BILLABLE CODE

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Abnormal drug tolerance
  • Abnormal hormone secretion
  • Abnormal movement
  • Abnormality of secretion of gastrin
  • Acanthosis nigricans
  • Acneiform drug eruption
  • Acneiform eruption
  • Acquired acanthosis nigricans
  • Acquired central hypothyroidism
  • Acquired coagulation factor inhibitor disorder
  • Acquired coagulation factor inhibitor disorder
  • Acquired coagulation factor inhibitor disorder
  • Acquired coagulation factor inhibitor disorder
  • Acquired epidermolysis bullosa
  • Acquired long QT syndrome
  • Acquired thrombotic thrombocytopenic purpura
  • Acute akathisia caused by drug
  • Acute drug-induced gout
  • Acute drug-induced interstitial lung disorder
  • Acute drug-induced tubulointerstitial nephritis
  • Acute drug-induced ulcer of stomach
  • Acute drug-induced ulcer of stomach
  • Acute edema
  • Acute erythema
  • Acute erythema
  • Acute erythema
  • Acute erythematous eruption of skin
  • Acute erythematous eruption of skin
  • Acute erythematous eruption of skin
  • Acute febrile neutrophilic dermatosis
  • Acute gastric erosion associated with drug ingestion
  • Acute gout
  • Acute hepatic failure
  • Acute hepatic failure due to drugs
  • Acute pulmonary edema
  • Acute tubulointerstitial nephritis
  • Adverse cutaneous reaction to volatile oil
  • Adverse drug interaction
  • Adverse drug interaction
  • Adverse drug interaction
  • Adverse drug interaction
  • Adverse drug interaction
  • Adverse drug interaction
  • Adverse drug interaction with dietary supplement
  • Adverse drug interaction with herbal supplement
  • Adverse drug interaction with over-the-counter medication
  • Adverse drug interaction with prescription medication
  • Adverse drug interaction with tobacco
  • Adverse medication interaction with medication
  • Adverse medication interaction with medication
  • Adverse medication interaction with medication
  • Adverse reaction following injection of substance
  • Adverse reaction following injection of substance
  • Adverse reaction to biological substance
  • Adverse reaction to drug
  • Adverse reaction to lipotropic drugs
  • Adverse reaction to oil
  • Adverse reaction to pharmaceutical excipient
  • Adverse reaction to substance applied to neonatal skin
  • Akathisia
  • Akathisia
  • Akathisia caused by drug
  • Allergic contact dermatitis due to drug in contact with skin
  • Allergic disorder monitoring status
  • Allergic hepatitis
  • Allergic reaction after allergen immunotherapy
  • Allergic reaction after allergen immunotherapy
  • Allergic reaction due to allergy skin test
  • Allergic reaction to colophony
  • Allergic reaction to drug
  • Allergic sensitization
  • Allergic sensitization by patch test
  • Allergy drug side effect
  • Anagen effluvium
  • Anagen effluvium caused by drug
  • Anaphylaxis after allergen immunotherapy
  • Anastomotic ulcer of stomach caused by drug
  • Androgen excess caused by drug
  • Androgen level above reference range
  • Anemia due to medication
  • Annular erythema
  • Annular erythema due to drug
  • Aplasia cutis congenita due to teratogenic drug
  • Aseptic meningitis
  • Aseptic meningitis due to drug
  • Aseptic peritonitis
  • Atrophy of skin due to drug
  • Atrophy of skin due to drug
  • Atypical fracture of femur
  • Autoimmune bullous dermatosis due to drug
  • Autoimmune bullous dermatosis due to drug
  • Autoimmune bullous dermatosis due to drug
  • Autoimmune bullous dermatosis due to drug
  • Autoimmune bullous dermatosis due to drug
  • Autonomic neuropathy due to diabetes mellitus
  • Autonomic neuropathy due to drug induced diabetes mellitus
  • Autonomic neuropathy due to medication induced hypoglycemia
  • Azoospermia due to drug
  • B cell lymphocyte aplasia caused by drug
  • B-cell pseudolymphoma due to drug
  • Benign intracranial hypertension
  • Benign intracranial hypertension due to drug
  • Benign mucous membrane pemphigoid
  • Bilateral cataract of eyes caused by drug
  • Bilateral glaucoma of eyes caused by drug
  • Bilateral keratopathy caused by drug
  • Bilateral open-angle glaucoma
  • Bilateral osteonecrosis of femurs caused by drug
  • Blistering of skin due to drug-induced coma
  • Blistering of skin due to drug-induced coma
  • Blood disorder monitoring status
  • Blood drug side effect
  • Bronchospasm
  • Bronchospasm caused by drug
  • Bullae and sweat gland necrosis in drug-induced coma
  • Bullous dermatosis precipitated by drug treatment
  • Bullous dermatosis precipitated by drug treatment
  • Bullous dermatosis precipitated by drug treatment
  • Bullous dermatosis precipitated by drug treatment
  • Bullous dermatosis precipitated by drug treatment
  • Bullous pemphigoid
  • Capillaritis due to drug
  • Cardiomyopathy caused by drug
  • Cataract due to diabetes mellitus
  • Cataract due to drug induced diabetes mellitus
  • Central hypothyroidism
  • Central nervous system depression
  • Central sleep apnea syndrome
  • Cheilitis medicamentosa
  • Chemical peritonitis
  • Cholangiohepatitis
  • Cholestatic hepatitis
  • Cholestatic jaundice caused by drug
  • Cholestatic jaundice syndrome
  • Chorea due to tardive dyskinesia
  • Chronic bilateral vestibulopathy caused by ototoxic agent
  • Chronic cicatrizing conjunctivitis caused by drug
  • Chronic disease - drug side effects
  • Chronic drug-induced interstitial lung disorders
  • Chronic drug-induced renal disease
  • Chronic drug-induced tubulointerstitial nephritis
  • Chronic drug-induced ulcer of stomach
  • Chronic follicular conjunctivitis due to drug
  • Chronic gout caused by drug
  • Chronic gout of ankle and/or foot without tophus caused by drug
  • Chronic gout of elbow without tophus caused by drug
  • Chronic gout of hand without tophus caused by drug
  • Chronic gout of hip without tophus caused by drug
  • Chronic gout of knee without tophus caused by drug
  • Chronic gout of multiple sites without tophus caused by drug
  • Chronic gout of shoulder without tophus caused by drug
  • Chronic gout of vertebra without tophus caused by drug
  • Chronic gout of wrist without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic gout without tophus caused by drug
  • Chronic kidney disease stage 1
  • Chronic kidney disease stage 1 due to drug induced diabetes mellitus
  • Chronic kidney disease stage 2
  • Chronic kidney disease stage 2 due to drug induced diabetes mellitus
  • Chronic kidney disease stage 3 due to drug induced diabetes mellitus
  • Chronic kidney disease stage 4
  • Chronic kidney disease stage 4 due to drug induced diabetes mellitus
  • Chronic kidney disease stage 5 due to drug induced diabetes mellitus
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout caused by drug
  • Chronic tophaceous gout of ankle and/or foot caused by drug
  • Chronic tophaceous gout of elbow caused by drug
  • Chronic tophaceous gout of hand caused by drug
  • Chronic tophaceous gout of hip caused by drug
  • Chronic tophaceous gout of knee caused by drug
  • Chronic tophaceous gout of multiple sites caused by drug
  • Chronic tophaceous gout of shoulder caused by drug
  • Chronic tophaceous gout of vertebra caused by drug
  • Chronic tophaceous gout of wrist caused by drug
  • Chronic toxic interstitial nephritis
  • Cicatrizing conjunctivitis
  • Cicatrizing conjunctivitis
  • Color changes during tooth formation
  • Conjugated hyperbilirubinemia
  • Conjunctival adrenochrome deposits
  • Conjunctival deposit due to drug
  • Conjunctivitis caused by drug
  • Conjunctivitis caused by drug
  • Conjunctivitis caused by drug
  • Conjunctivitis caused by drug
  • Constricted pupil
  • Constricted pupil
  • Cutaneous B-cell pseudolymphoma
  • Cutaneous inflammation due to cytotoxic therapy
  • Cutaneous T-cell pseudolymphoma
  • Cutaneous ulceration due to cytotoxic therapy
  • Cytopenia caused by drug
  • Dermatosis resulting from cytotoxic therapy
  • Dermatosis resulting from cytotoxic therapy
  • Dermatosis resulting from cytotoxic therapy
  • Dermatosis resulting from cytotoxic therapy
  • Dermatosis resulting from cytotoxic therapy
  • Diabetes mellitus induced by non-steroid drugs
  • Diabetes mellitus induced by non-steroid drugs without complication
  • Diarrhea due to drug
  • Diffuse alopecia
  • Dilated cardiomyopathy secondary to drug
  • Disorder of autonomic nervous system caused by drug
  • Disorder of autonomic nervous system caused by drug
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of kidney due to drug induced diabetes mellitus
  • Disorder of nail color
  • Disorder of nail color
  • Disorder of vision due to secondary diabetes mellitus
  • Disturbance of hair cycle
  • Disturbance of hair cycle
  • Dizziness due to drug
  • Dizziness due to drug
  • Dose-related drug-induced neutropenia
  • Drug exanthem
  • Drug induced acquired central hypothyroidism
  • Drug induced anal ulceration
  • Drug induced central sleep apnea
  • Drug induced dysfunction of vestibular system
  • Drug induced lacrimal canalicular stenosis
  • Drug induced pulmonary fibrosis
  • Drug induced pulmonary fibrosis
  • Drug induced thrombotic thrombocytopenic purpura
  • Drug induction of cytochrome p450 CYP1A2 enzyme
  • Drug induction of cytochrome p450 CYP2C19 enzyme
  • Drug induction of cytochrome p450 CYP2C9 enzyme
  • Drug induction of cytochrome p450 CYP3A enzyme
  • Drug inhibition of cytochrome p450 CYP1A2 enzyme
  • Drug inhibition of cytochrome p450 CYP2C19 enzyme
  • Drug inhibition of cytochrome p450 CYP2C9 enzyme
  • Drug inhibition of cytochrome p450 CYP2D6 enzyme
  • Drug inhibition of cytochrome p450 CYP3A enzyme
  • Drug interaction with drug
  • Drug interaction with drug
  • Drug interaction with drug
  • Drug interaction with tobacco
  • Drug interaction with tobacco
  • Drug pigmentation
  • Drug pigmentation
  • Drug pigmentation
  • Drug pigmentation
  • Drug pigmentation
  • Drug reaction AND/OR intoxication specific to newborn
  • Drug reaction AND/OR intoxication specific to newborn
  • Drug reaction with eosinophilia and systemic symptoms
  • Drug related visual impairment
  • Drug tolerance
  • Drug-aggravated angioedema-urticaria
  • Drug-exacerbated psoriasis
  • Drug-induced acanthosis nigricans
  • Drug-induced acute cicatrizing conjunctivitis
  • Drug-induced acute dystonia
  • Drug-induced acute pancreatitis
  • Drug-induced acute pulmonary edema
  • Drug-induced adrenocortical insufficiency
  • Drug-induced adrenogenital disorder
  • Drug-induced anaphylaxis
  • Drug-induced androgenic alopecia
  • Drug-induced anetoderma
  • Drug-induced angioedema-urticaria
  • Drug-induced apnea
  • Drug-induced asthma
  • Drug-induced autoimmune hemolytic anemia
  • Drug-induced autoimmune reaction
  • Drug-induced autonomic dysfunction
  • Drug-induced bradycardia
  • Drug-induced bradycardia
  • Drug-induced bronchiolitis obliterans
  • Drug-induced bullous pemphigoid
  • Drug-induced cataract
  • Drug-induced cataract
  • Drug-induced central nervous system depression
  • Drug-induced cerebellar ataxia
  • Drug-induced cholestatic hepatitis
  • Drug-induced chorea
  • Drug-induced chronic hepatitis
  • Drug-induced chronic pancreatitis
  • Drug-induced cicatricial pemphigoid
  • Drug-induced cirrhosis of liver
  • Drug-induced coagulation inhibitor disorder
  • Drug-induced coagulation inhibitor disorder
  • Drug-induced coagulation inhibitor disorder
  • Drug-induced colitis
  • Drug-induced coma
  • Drug-induced constipation
  • Drug-induced corneal epithlelial deposit
  • Drug-induced cutis laxa
  • Drug-induced dermatomyositis
  • Drug-induced dermatosis
  • Drug-induced desquamation of skin
  • Drug-induced diabetes mellitus
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of cornea
  • Drug-induced disorder of liver
  • Drug-induced disorder of refraction AND/OR accommodation
  • Drug-induced disorder of refraction AND/OR accommodation
  • Drug-induced dyskinesia
  • Drug-induced dyskinesia
  • Drug-induced dyskinesia
  • Drug-induced dyskinesia
  • Drug-induced dyskinesia, acute onset
  • Drug-induced dystonia
  • Drug-induced dystonia
  • Drug-induced dystonia
  • Drug-induced dystonia
  • Drug-induced embolism
  • Drug-induced encephalopathy
  • Drug-induced enteritis of intestine
  • Drug-induced enteritis of intestine
  • Drug-induced enzyme deficiency anemia
  • Drug-induced eosinophilia
  • Drug-induced epidermolysis bullosa acquisita
  • Drug-induced epilepsy
  • Drug-induced erythema multiforme
  • Drug-induced erythema nodosum
  • Drug-induced erythromelalgia
  • Drug-induced feminization
  • Drug-induced fibrinolytic disorder
  • Drug-induced flushing
  • Drug-induced gastrointestinal disturbance
  • Drug-induced gingival hyperplasia
  • Drug-induced glaucoma
  • Drug-induced glaucoma
  • Drug-induced glaucoma
  • Drug-induced glaucoma
  • Drug-induced granulomatous mediastinitis
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair abnormality
  • Drug-induced hair color change
  • Drug-induced hepatic necrosis
  • Drug-induced hepatitis
  • Drug-induced hepatitis
  • Drug-induced hirsutism
  • Drug-induced hypergastrinemia
  • Drug-induced hyperglycemia
  • Drug-induced hyperhidrosis
  • Drug-induced hyperinsulinemia
  • Drug-induced hyperkalemia
  • Drug-induced hypermelanosis
  • Drug-induced hypermelanosis
  • Drug-induced hypermelanosis
  • Drug-induced hyperprolactinemia
  • Drug-induced hyperpyrexia
  • Drug-induced hypersomnia
  • Drug-induced hypertrichosis
  • Drug-induced hypocalcemia
  • Drug-induced hypoglycemia
  • Drug-induced hypoglycemia without coma
  • Drug-induced hypokalemia
  • Drug-induced hypomagnesemia
  • Drug-induced hypomelanosis
  • Drug-induced hyponatremia
  • Drug-induced hypoplasia of bone marrow
  • Drug-induced hypotension
  • Drug-induced ichthyosiform reaction
  • Drug-induced ileus
  • Drug-induced immune hemolytic anemia, hapten type
  • Drug-induced immune hemolytic anemia, immune complex type
  • Drug-induced immunodeficiency
  • Drug-induced interstitial lung disorder
  • Drug-induced interstitial lung disorder
  • Drug-induced interstitial lung disorder
  • Drug-induced interstitial lung disorder
  • Drug-induced intrahepatic cholestasis
  • Drug-induced keratoconjunctivitis
  • Drug-induced lesion
  • Drug-induced leukonychia
  • Drug-induced linear IgA disease
  • Drug-induced lupus erythematosus
  • Drug-induced lymphocytic vasculitis
  • Drug-induced malabsorption
  • Drug-induced male infertility
  • Drug-induced megacolon
  • Drug-induced melasma
  • Drug-induced membranous nephropathy
  • Drug-induced methemoglobinemia
  • Drug-induced mucositis
  • Drug-induced myasthenia
  • Drug-induced myoclonus
  • Drug-induced myopathy
  • Drug-induced nail abnormality
  • Drug-induced nail abnormality
  • Drug-induced nail abnormality
  • Drug-induced nail fragility
  • Drug-induced nail hypertrophy
  • Drug-induced nausea and vomiting
  • Drug-induced necrotizing vasculitis
  • Drug-induced neutropenia
  • Drug-induced neutrophilia
  • Drug-induced non autoimmune hemolytic anemia
  • Drug-induced obesity
  • Drug-induced oral condition
  • Drug-induced oral condition
  • Drug-induced oral condition
  • Drug-induced oral lichenoid reaction
  • Drug-induced oral pigmentation
  • Drug-induced oral ulceration
  • Drug-induced orofacial dyskinesia
  • Drug-induced osteoporosis
  • Drug-induced osteoporosis
  • Drug-induced osteoporosis with pathological fracture
  • Drug-induced palmoplantar pustular psoriasis
  • Drug-induced panniculitis
  • Drug-induced panniculitis
  • Drug-induced pellagra
  • Drug-induced pemphigus
  • Drug-induced pemphigus foliaceus
  • Drug-induced pemphigus vulgaris
  • Drug-induced peptic ulcer
  • Drug-induced pericarditis
  • Drug-induced persistent light reaction
  • Drug-induced photo-onycholysis
  • Drug-induced photosensitivity
  • Drug-induced photosensitivity
  • Drug-induced photosensitivity
  • Drug-induced pigmentation
  • Drug-induced pigmentation of cornea
  • Drug-induced pleural effusion
  • Drug-induced pleurisy
  • Drug-induced pneumonitis
  • Drug-induced pneumonitis
  • Drug-induced polymyositis
  • Drug-induced porphyria
  • Drug-induced pseudoporphyria
  • Drug-induced pseudoscleroderma
  • Drug-induced pseudoxanthoma elasticum
  • Drug-induced purpura
  • Drug-induced purpura
  • Drug-induced purpura
  • Drug-induced Raynaud's phenomenon
  • Drug-induced retinopathy
  • Drug-induced sideroblastic anemia
  • Drug-induced solar urticaria
  • Drug-induced Stevens-Johnson syndrome
  • Drug-induced stricture of esophagus
  • Drug-induced systemic lupus erythematosus
  • Drug-induced tardive dystonia
  • Drug-induced telangiectasia
  • Drug-induced thyroiditis
  • Drug-induced toxic pustuloderma
  • Drug-induced tubulointerstitial nephritis
  • Drug-induced ulceration
  • Drug-induced uveitis
  • Drug-induced virilization
  • Drug-induced xerostomia
  • Drug-related alopecia
  • Drug-related myocardial necrosis syndrome
  • Duodenal ulcer caused by drug
  • Duodenitis caused by drug
  • Dysfunction of vestibular system
  • Dysmotility of small intestine caused by drug
  • Effect of drug maladministration
  • Emollient adverse reaction
  • End stage renal disease on dialysis due to drug induced diabetes mellitus
  • End stage renal failure on dialysis
  • Endocrine alopecia
  • Endocrine drug side effect
  • Endocrine system complication of procedure
  • Endocrine system complication of procedure
  • Enlargement of alveolar ridge
  • ENT disorder monitoring status
  • ENT drug side effect
  • Epidermal fragility
  • Eruption due to drug
  • Erythroderma caused by drug
  • Erythromelalgia
  • Esophagitis medicamentosa
  • Exanthematous disorder
  • Excessive muscarinic activity
  • Exogenous pigmentation of oral mucosa
  • Extrinsic staining of teeth caused by drug
  • Factor IX inhibitor disorder
  • Factor V inhibitor disorder
  • Factor VIII inhibitor disorder
  • Falls
  • Falls caused by medication
  • Fat hypertrophy
  • Fat hypertrophy due to injected drug
  • Feminization
  • Fixed drug eruption
  • Fixed drug reaction
  • Fixed drug reaction
  • Fixed drug reaction
  • Fixed drug reaction affecting oral mucous membranes
  • Folate deficiency anemia, drug-induced
  • Gastric erosion
  • Gastric ulcer caused by drug
  • Gastric ulcer caused by drug
  • Gastric ulcer caused by drug
  • Gastric ulcer caused by drug
  • Gastritis medicamentosa
  • Gastritis medicamentosa
  • Gastroenteritis caused by drug
  • Generalized enamel hypoplasia associated with ingestion of drugs
  • Generalized rash
  • Generalized skin eruption caused by drug and medicament
  • Gingival disease due to drug
  • Gingival disease due to drug
  • Gingival disease due to drug
  • Gingival disease due to drug
  • Gingival enlargement exacerbated by drug
  • Gingivitis due to drug
  • Glaucoma of left eye caused by drug
  • Glaucoma of left eye caused by drug
  • Glaucoma of right eye caused by drug
  • Glaucoma of right eye caused by drug
  • Gout of ankle and/or foot caused by drug
  • Gout of ankle and/or foot caused by drug
  • Gout of ankle and/or foot caused by drug
  • Gout of elbow caused by drug
  • Gout of elbow caused by drug
  • Gout of elbow caused by drug
  • Gout of hand caused by drug
  • Gout of hand caused by drug
  • Gout of hand caused by drug
  • Gout of hip caused by drug
  • Gout of hip caused by drug
  • Gout of hip caused by drug
  • Gout of knee caused by drug
  • Gout of knee caused by drug
  • Gout of knee caused by drug
  • Gout of multiple sites caused by drug
  • Gout of shoulder caused by drug
  • Gout of shoulder caused by drug
  • Gout of shoulder caused by drug
  • Gout of vertebra caused by drug
  • Gout of vertebra caused by drug
  • Gout of vertebra caused by drug
  • Gout of wrist caused by drug
  • Gout of wrist caused by drug
  • Gout of wrist caused by drug
  • Gout secondary to drug
  • Granulomatous mediastinitis
  • Gray syndrome from chloramphenicol administration in newborn
  • Gyne. drug side effect
  • Gynecologic disorder monitoring status
  • Hapten type high affinity hemolytic anemia
  • Hapten type low affinity hemolytic anemia
  • Headache caused by drug
  • Headache caused by drug
  • Heart block due to drug
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Hemolytic anemia due to drugs
  • Herbal medicine adverse reaction
  • High risk drug monitoring status
  • High risk drug side effect
  • Hirsutism
  • Homeopathic medicine adverse reaction
  • Hot flash due to medication
  • Hypercalcemia due to a drug
  • Hyperkalemia
  • Hyperosmolar coma due to diabetes mellitus
  • Hyperosmolar coma due to drug induced diabetes mellitus
  • Hyperosmolar coma due to secondary diabetes mellitus
  • Hyperosmolarity due to drug induced diabetes mellitus
  • Hyperosmolarity due to secondary diabetes mellitus
  • Hyperplasia of gingiva
  • Hyperpyrexia
  • Hypersensitivity disease of liver caused by drug
  • Hypersensitivity disease of liver caused by drug
  • Hypertension secondary to drug
  • Hypertrophy of nail
  • Hypocellular bone marrow
  • Hypophysectomy-induced hypopituitarism
  • Hypopituitarism caused by drug
  • Hyposecretion of salivary gland
  • Hypospermatogenesis
  • Hypothyroidism caused by drug
  • Iatrogenic adrenal insufficiency
  • Iatrogenic hypoglycemia
  • Iatrogenic hypopituitarism
  • Iatrogenic pituitary disorder
  • Iatrogenic thyroiditis
  • Idiosyncratic drug effect
  • Immune complex small vessel vasculitis caused by drug
  • Immune complex urticaria
  • Immunodeficiency caused by long term therapeutic use of drug
  • Impaired glucose tolerance associated with drugs
  • Increased gastrin secretion
  • Induced spermatogenic arrest
  • Infertility due to drug therapy
  • Inflammatory red colored lesion of internal part of mouth caused by drug
  • Insufficiency fracture
  • Interstitial pulmonary fibrosis due to inhalation of drug
  • Interstitial pulmonary fibrosis due to inhalation of substance
  • Intolerance to drug
  • Intractable headache caused by drug
  • Intraoperative floppy iris syndrome
  • Intraoperative floppy iris syndrome
  • Intraoperative floppy iris syndrome of left eye
  • Intraoperative floppy iris syndrome of right eye
  • Intravenous nutrition adverse reaction
  • Intravenous nutrition adverse reaction
  • Intravenous nutrition adverse reaction
  • Intravenous nutrition adverse reaction
  • Intrinsic staining of tooth - drug-induced
  • Irritant contact dermatitis due to drug in contact with skin
  • Keratopathy medicamentosa
  • Keratopathy of left eye caused by drug
  • Keratopathy of right eye caused by drug
  • Leukopenia caused by drug
  • Lichenoid drug eruption
  • Linear IgA dermatosis
  • Localized eruption of skin
  • Localized pustular psoriasis
  • Localized skin eruption caused by drug and medicament
  • Long QT syndrome caused by drug
  • Lubricant adverse reaction
  • Lyell syndrome
  • Lymphocyte count below reference range
  • Lymphocytic vasculitis of skin
  • Maculopapular drug eruption
  • Maculopapular eruption
  • Male pattern alopecia
  • Medication bezoar
  • Medication overuse headache
  • Medication side effects present
  • Medication-induced movement disorder
  • Medication-induced postural tremor
  • Megaloblastic anemia due to drugs
  • Megaloblastic anemia due to drugs
  • Motility disorder of small intestine
  • Multiple drug intolerant hypertension
  • Myelofibrosis
  • Myelofibrosis caused by drug
  • Myocarditis due to drug
  • Myotonia due to drug
  • Nail color change due to ingested drug
  • Nail dystrophy due to cytotoxic therapy
  • Nail fragility
  • Nausea and vomiting
  • Neonatal jaundice caused by drug transmitted from mother
  • Neonatal perforation of intestine caused by drug
  • Nephritis caused by drug
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Nephropathy due to secondary diabetes mellitus
  • Neuroleptic-induced acute dystonia
  • Neurological disorder monitoring status
  • Neurological drug side effects
  • Neuropathy associated with hypoglycemia
  • Neutrophilia disorder
  • Neutrophilic eccrine hidradenitis
  • Neutrophilic eccrine hidradenitis due to cytotoxic therapy
  • Newborn drug intoxication
  • Newborn drug intoxication
  • Newborn drug reaction
  • Newborn drug reaction
  • Newborn drug reaction and intoxication
  • Niacin deficiency
  • Non dose-related adverse reaction to medication
  • Non dose-related drug-induced neutropenia
  • Non-allergic anaphylaxis caused by drug
  • Non-autoimmune hemolytic anemia
  • Non-diabetic hypoglycemia
  • Non-diabetic hypoglycemia
  • Non-melanin pigmentation due to drug
  • Non-pigmenting fixed drug eruption
  • Obstructive hyperbilirubinemia
  • Ocular cicatricial pemphigoid
  • Oligozoospermia
  • Oligozoospermia due to drug therapy
  • Onycholysis
  • Oral lichenoid reaction
  • Organic sleep disorder
  • Organic sleep related movement disorder
  • Orofacial dyskinesia
  • Osteomalacia secondary to drug
  • Osteonecrosis caused by drug
  • Osteonecrosis of ankle caused by drug
  • Osteonecrosis of carpus caused by drug
  • Osteonecrosis of femur caused by drug
  • Osteonecrosis of femur caused by drug
  • Osteonecrosis of fibula caused by drug
  • Osteonecrosis of finger caused by drug
  • Osteonecrosis of hand caused by drug
  • Osteonecrosis of hand caused by drug
  • Osteonecrosis of jaw
  • Osteonecrosis of jaw caused by drug
  • Osteonecrosis of pelvis caused by drug
  • Osteonecrosis of radius caused by drug
  • Osteonecrosis of shoulder caused by drug
  • Osteonecrosis of tibia caused by drug
  • Osteonecrosis of toe caused by drug
  • Osteopenia caused by drug
  • Ototoxicity
  • Ototoxicity - labyrinthine
  • Pain following administration of agent
  • Palpation thyroiditis
  • Parkinsonism due to drug
  • Pellagra
  • Pemphigus foliaceus
  • Pemphigus vulgaris
  • Persistent miosis
  • Persistent miosis
  • Pharmaceutical fluid or solution adverse reaction
  • Pharmacologic parasympathicotonic pupil
  • Pharmacological paralysis of accommodation
  • Photochemotherapy reaction
  • Photoonycholysis
  • Phototoxic drug eruption
  • Pill esophagitis
  • Pityriasis rosea-like drug eruption
  • Pleurothotonus
  • Polymyositis
  • Polyneuropathy due to diabetes mellitus
  • Polyneuropathy due to drug
  • Polyneuropathy due to drug induced diabetes mellitus
  • Polyneuropathy due to secondary diabetes mellitus
  • Posteruptive color change of tooth
  • Posteruptive color change of tooth
  • Posteruptive teeth staining
  • Posteruptive tooth staining due to drug
  • Posteruptive tooth staining due to drug
  • Pre-eruptive color change of tooth
  • Priapism
  • Priapism caused by drug
  • Pruritus caused by drug
  • Pseudolymphomatous eruption due to drug
  • Pseudolymphomatous eruption due to drug
  • Pseudolymphomatous eruption due to drug
  • Pseudoporphyria
  • Pseudoscleroderma due to cytotoxic therapy
  • Pseudoxanthoma elasticum
  • Psoriasiform drug eruption
  • Pulmonary arterial hypertension induced by drug
  • Pulmonary toxicity
  • Purpura due to drug-induced capillary damage
  • Purpura due to drug-induced coagulation abnormality
  • Pustular psoriasis of palm of hand
  • Pustular psoriasis of palms and soles
  • Pustular psoriasis of sole of foot
  • Radiation recall reaction due to cytotoxic therapy
  • Raynaud's phenomenon
  • Renal hypersensitivity caused by drug
  • Renal tubular defect
  • Renal tubular dysgenesis caused by drug
  • Restlessness
  • Restlessness
  • Retention of urine
  • Retention of urine caused by drug
  • Salivary dysfunction caries secondary to medication
  • Salivary dysfunction dental caries
  • Scleroderma-like secondary cutaneous sclerosis
  • Scleroderma-like secondary cutaneous sclerosis
  • Secondary acquired sideroblastic anemia
  • Secondary cerebellar degeneration
  • Secondary dental caries associated with local or systemic factors
  • Secondary hyperprolactinemia
  • Secondary hypomagnesemia
  • Serum sickness due to drug
  • Sinus bradycardia
  • Sinus bradycardia caused by drug
  • Skin peeling disorder
  • Sleep-related movement disorder caused by drug
  • Small vessel pulmonary hypertension
  • Small vessel vasculitis caused by immune complex
  • Solar urticaria
  • Solitary pulmonary hypertension
  • Spermatogenic arrest
  • Staining of teeth
  • Staining of teeth
  • Starch peritonitis
  • Stenosis of lacrimal canaliculi
  • Stevens Johnson syndrome AND toxic epidermal necrolysis overlap
  • Stevens-Johnson and toxic epidermal necrolysis overlap syndrome caused by drug
  • Stevens-Johnson syndrome
  • Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum
  • Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum
  • Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum
  • Stomatitis medicamentosa
  • Strength of nails - finding
  • Stricture of esophagus
  • Subacute dyskinesia due to drug
  • Substance induction of cytochrome p450 CYP1A2 enzyme
  • Substance induction of cytochrome p450 CYP3A enzyme
  • Substance induction of cytochrome p450 enzyme
  • Substance induction of cytochrome p450 enzyme
  • Substance induction of cytochrome p450 enzyme
  • Substance induction of cytochrome p450 enzyme
  • Substance inhibition of cytochrome p450 CYP3A enzyme
  • Substance inhibition of cytochrome p450 enzyme
  • Substance inhibition of cytochrome p450 enzyme
  • Substance inhibition of cytochrome p450 enzyme
  • Substance inhibition of cytochrome p450 enzyme
  • Substance inhibition of cytochrome p450 enzyme
  • Sweet's disease due to drug
  • Swelling of gingival and edentulous alveolar ridge due to drug
  • Swollen gums
  • Sympathoparetic pupil caused by drug
  • Syringosquamous metaplasia due to cytotoxic therapy
  • Tardive dyskinesia
  • T-cell pseudolymphoma due to drug
  • Teeth staining due to drugs
  • Teeth staining due to drugs
  • Telogen effluvium
  • Telogen hair loss caused by drug
  • Thrombocytopenia due to drugs
  • Thrombophilia due to drug therapy
  • Thrombotic microangiopathy
  • Thrombotic thrombocytopenic purpura
  • Tic caused by drug
  • Torsades de pointe caused by drug
  • Torsades de pointes
  • Toxic adverse drug interaction with drug
  • Toxic disorder of refraction AND/OR accommodation
  • Toxic disorder of refraction AND/OR accommodation
  • Toxic enteritis of small intestine caused by drug
  • Toxic enteritis of small intestine caused by drug
  • Toxic epidermal necrolysis due to drug
  • Toxic keratoconjunctivitis
  • Toxic neuromuscular junction disorder
  • Toxic polyneuropathy
  • Tremor due to substance abuse
  • Ulcer of anus
  • Ulcer of esophagus due to ingestion of medicines
  • Ulcer of foot due to drug induced diabetes mellitus
  • Ultraviolet recall reaction due to cytotoxic therapy
  • Urticaria medicamentosa
  • Urticaria medicamentosa
  • Urticaria medicamentosa
  • Vasculitis secondary to drug
  • Ventricular tachycardia, polymorphic
  • Vertigo caused by drug
  • Vitamin B12 deficiency anemia caused by drug
  • Xerostomia

Clinical Information

  • Laminaria

    a genus of brown algae in the family laminariaceae. dried pencil-like pieces may be inserted in the cervix where they swell as they absorb moisture, serving as osmotic dilators.
  • Saccharin

    flavoring agent and non-nutritive sweetener.
  • 1,4-alpha-Glucan Branching Enzyme

    in glycogen or amylopectin synthesis, the enzyme that catalyzes the transfer of a segment of a 1,4-alpha-glucan chain to a primary hydroxy group in a similar glucan chain. ec 2.4.1.18.
  • Electrophoresis, Starch Gel

    electrophoresis in which a starch gel (a mixture of amylose and amylopectin) is used as the diffusion medium.
  • Hydroxyethyl Starch Derivatives

    starches that have been chemically modified so that a percentage of oh groups are substituted with 2-hydroxyethyl ether groups.
  • Starch

    any of a group of polysaccharides of the general formula (c6-h10-o5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin. it is the chief storage form of energy reserve (carbohydrates) in plants.
  • Starch Phosphorylase

    an enzyme of the phosphorylases family that catalyzes the degradation of starch, a mixture of unbranched amylose and branched amylopectin compounds. this phosphorylase from plants is the counterpart of glycogen phosphorylase in animals that catalyzes the reaction of inorganic phosphate on the terminal alpha-1,4-glycosidic bond at the non-reducing end of glucans resulting in the release of glucose-1-phosphate.
  • Starch Synthase

    an enzyme that catalyzes the transfer of glucose from adpglucose to glucose-containing polysaccharides in 1,4-alpha-linkages. ec 2.4.1.21.
  • Tardive Dyskinesia

    drug-related movement disorder characterized by uncontrollable movements in certain muscles. it is associated with a long-term exposure to certain neuroleptic medications (e.g., metoclopramide).
  • Hyperkalemia

    abnormally high potassium concentration in the blood, most often due to defective renal excretion. it is characterized clinically by electrocardiographic abnormalities (elevated t waves and depressed p waves, and eventually by atrial asystole). in severe cases, weakness and flaccid paralysis may occur. (dorland, 27th ed)
  • Pseudohypoaldosteronism

    a heterogeneous group of disorders characterized by renal electrolyte transport dysfunctions. congenital forms are rare autosomal disorders characterized by neonatal hypertension, hyperkalemia, increased renin activity and aldosterone concentration. the type i features hyperkalemia with sodium wasting; type ii, hyperkalemia without sodium wasting. pseudohypoaldosteronism can be the result of a defective renal electrolyte transport protein or acquired after kidney transplantation.
  • Pseudoxanthoma Elasticum

    an inherited disorder of connective tissue with extensive degeneration and calcification of elastic tissue primarily in the skin, eye, and vasculature. at least two forms exist, autosomal recessive and autosomal dominant. this disorder is caused by mutations of one of the atp-binding cassette transporters. patients are predisposed to myocardial infarction and gastrointestinal hemorrhage.
  • Dermatomyositis

    a subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. the illness occurs with approximately equal frequency in children and adults. the skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. the disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. the childhood form of this disease tends to evolve into a systemic vasculitis. dermatomyositis may occur in association with malignant neoplasms. (from adams et al., principles of neurology, 6th ed, pp1405-6)
  • Polymyositis

    diseases characterized by inflammation involving multiple muscles. this may occur as an acute or chronic condition associated with medication toxicity (drug toxicity); connective tissue diseases; infections; malignant neoplasms; and other disorders. the term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. the illness may occur at any age, but is most frequent in the fourth to sixth decade of life. weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (adams et al., principles of neurology, 6th ed, pp1404-9)
  • Torsades de Pointes

    a malignant form of polymorphic ventricular tachycardia that is characterized by heart rate between 200 and 250 beats per minute, and qrs complexes with changing amplitude and twisting of the points. the term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long qt intervals exceeding 500 milliseconds or bradycardia. torsades de pointes may be self-limited or may progress to ventricular fibrillation.
  • Erythromelalgia

    a peripheral arterial disease that is characterized by the triad of erythema, burning pain, and increased skin temperature of the extremities (or red, painful extremities). erythromelalgia may be classified as primary or idiopathic, familial or non-familial. secondary erythromelalgia is associated with other diseases, the most common being myeloproliferative disorders.
  • Hirsutism

    a condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. it is the result of elevated androgens from the ovaries, the adrenal glands, or exogenous sources. the concept does not include hypertrichosis, which is an androgen-independent excessive hair growth.
  • Acanthosis Nigricans

    a circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. it occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.
  • Pellagra

    a disease due to deficiency of niacin, a b-complex vitamin, or its precursor tryptophan. it is characterized by scaly dermatitis which is often associated with diarrhea and dementia (the three d's).
  • Androgen-Insensitivity Syndrome

    a disorder of sexual development transmitted as an x-linked recessive trait. these patients have a karyotype of 46,xy with end-organ resistance to androgen due to mutations in the androgen receptor (receptors, androgen) gene. severity of the defect in receptor quantity or quality correlates with their phenotypes. in these genetic males, the phenotypic spectrum ranges from those with normal female external genitalia, through those with genital ambiguity as in reifenstein syndrome, to that of a normal male with infertility.
  • Feminization

    development of female secondary sex characteristics in the male. it is due to the effects of estrogenic metabolites of precursors from endogenous or exogenous sources, such as adrenal glands or therapeutic drugs.
  • Priapism

    a prolonged painful erection that may lasts hours and is not associated with sexual activity. it is seen in patients with sickle cell anemia, advanced malignancy, spinal trauma; and certain drug treatments.
  • Onycholysis

    separation of nail plate from the underlying nail bed. it can be a sign of skin disease, infection (such as onychomycosis) or tissue injury.
  • Xerostomia

    decreased salivary flow.
  • Drug Tolerance

    progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. it should be differentiated from drug resistance wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. it should also be differentiated from maximum tolerated dose and no-observed-adverse-effect level.
  • Ototoxicity

    damage to the ear or its function secondary to exposure to toxic substances such as drugs used in chemotherapy; immunotherapy; or radiation.
  • Metoclopramide

    a dopamine d2 antagonist that is used as an antiemetic.
  • Onychomycosis

    a fungal infection of the nail, usually caused by dermatophytes; yeasts; or nondermatophyte molds.
  • Grade 1 Hyperkalemia, CTCAE|Grade 1 Hyperkalemia

    >uln-5.5 mmol/l
  • Grade 2 Hyperkalemia, CTCAE|Grade 2 Hyperkalemia

    >5.5-6.0 mmol/l; intervention initiated
  • Grade 3 Hyperkalemia, CTCAE|Grade 3 Hyperkalemia

    >6.0-7.0 mmol/l; hospitalization indicated
  • Grade 4 Hyperkalemia, CTCAE|Grade 4 Hyperkalemia

    >7.0 mmol/l; life-threatening consequences
  • Grade 5 Hyperkalemia, CTCAE|Grade 5 Hyperkalemia

    death
  • Hyperkalemia

    higher than normal levels of potassium in the circulating blood; associated with kidney failure or sometimes with the use of diuretic drugs.
  • Hyperkalemia, CTCAE|Hyperkalemia|Hyperkalemia

    a disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.
  • Hyperkalemic Mineralocorticoid Resistance|Chloride Shunt Syndrome|Familial Hyperkalemic Hypertension|Gordon Hyperkalemia|Mineralocorticoid Resistant Hyperkalemia|PHA Type 2|Pseudohypoaldosteronism, Type II|Spitzer-Weinstein Syndrome

    a genetically heterogynous condition characterized by hyperkalemia, hyperchloremic acidosis, low or suppressed renin activity, and normal to high concentrations of aldosterone. mutations in genes (for example wnk1 or wnk4), regulating na-cl cotransporters (ncc), na-k-cl cotransporters (nkcc2), or the renal outer medullary potassium (romk) channel have been identified as causative in this condition. the primary abnormality is thought to be a specific defect of the renal secretory mechanism for potassium, which limits the kaliuretic response to, but not the sodium and chloride reabsorptive effect of, mineralocorticoid.
  • Chemical Peritonitis

    a non-infectious inflammation of the peritoneum.
  • Neutrophilic Eccrine Hidradenitis

    painful red or pink edematous nodules most commonly found on the palmar and/or plantar regions.
  • ABCC6 wt Allele|ABC34|ARA|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6 wt Allele|ATP-Binding Cassette, Subfamily C, Member 6 Gene|EST349056|GACI2|MLP1|MOAT-E|MOATE|MRP6|PXE|PXE1|Pseudoxanthoma Elasticum Gene|URG7

    human abcc6 wild-type allele is located in the vicinity of 16p13.1 and is approximately 75 kb in length. this allele, which encodes multidrug resistance-associated protein 6, plays a role in the active transport of drugs across the plasma membrane. mutation of the gene is associated with pseudoxanthoma elasticum and generalized arterial calcification of infancy type 2.
  • Pseudoxanthoma Elasticum

    a rare, progressive, autosomal recessive inherited disorder caused by mutations in the abcc6 gene. it is characterized by calcification and fragmentation of the elastic fibers of the skin, retina, and cardiovascular system. signs and symptoms include skin plaques and bumps, thickened skin, retinal hemorrhage and obstruction of the blood vessels.
  • Spastic Paraplegia 56|Autosomal Recessive Spastic Paraplegia-56 with or without Pseudoxanthoma Elasticum|SPG56

    an autosomal recessive subtype of hereditary spastic paraplegia caused by mutation(s) in the cyp2u1 gene, encoding cytochrome p450 2u1.
  • Central Sleep Apnea Syndrome

    a broad classification of disorders which includes 6 subtypes (primary central sleep apnea, central sleep apnea due to cheyne-stokes breathing pattern, central sleep apnea due to medical condition not cheyne-stokes, central sleep apnea due to high-altitude periodic breathing, central sleep apnea due to drug or substance and primary sleep apnea of infancy) that are each characterized by interruptions in breathing while asleep. it is caused by improper signaling from the brainstem to respiratory muscles and is triggered by either hypoventilation or hyperventilation. in adults, this disorder may arise following a stroke, congestive heart failure, trauma, infection or the use of narcotic medications. it is more common in older males and may present as a co-morbid condition to obesity. clinical signs include snoring, insomnia or hypersomnia, difficulty concentrating and fatigue. recurrent episodes of hypoxia/hypoxemia have long-term detrimental effects on cardiovascular health.
  • Akathisia

    an uncomfortable feeling of inner restlessness and inability to stay still. it can be a side effect of psychotropic medications.
  • Akathisia, CTCAE|Akathisia|Akathisia

    a disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.
  • Barnes Akathisia Rating Scale Clinical Classification|BARS|BARS|BARS01

    a standardized rating scale developed by thomas r. e. barnes in 1989 to diagnose akathisia associated with use of antipsychotic agents. this instrument contains objective and subjective sections, as well as a global clinical assessment of akathisia. the first two sections contain a total of 3 items which are rated on a scale of 0 to 3 with 0 being none or normal and 3 being severe. the third section is rated on a 0 to 5 scale with 0 being none and 5 being severe.
  • CDISC Clinical Classification BARS Test Code Terminology|BARS01TC|Barnes Akathisia Rating Scale Clinical Classification Test Code|QS-BARS TESTCD

    test codes of clinical classification questions associated with the barnes akathisia rating scale (bars) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).
  • CDISC Clinical Classification BARS Test Name Terminology|BARS01TN|Barnes Akathisia Rating Scale Clinical Classification Test Name|QS-BARS TEST

    test names of clinical classification questions associated with the barnes akathisia rating scale (bars) for the clinical data interchange standards consortium (cdisc) standard data tabulation model (sdtm).
  • Drug-Induced Akathisia|Drug induced akathisia

    evidence of drug-induced akathisia.
  • ESRS-A - Akathisia: Objective|ESRSA1-Akathisia: Objective|ESRSA1-Akathisia: Objective|ESRSA124

    extrapyramidal symptom rating scale-abbreviated (esrs-a) akathisia: objective.
  • ESRS-A - Akathisia: Subjective|ESRSA1-Akathisia: Subjective|ESRSA1-Akathisia: Subjective|ESRSA123

    extrapyramidal symptom rating scale-abbreviated (esrs-a) akathisia: subjective.
  • ESRS-A - CGI-S Akathisia|ESRSA1-CGI-S Akathisia|ESRSA1-CGI-S Akathisia|ESRSA128

    extrapyramidal symptom rating scale-abbreviated (esrs-a) clinical global impression (cgi-s): akathisia.
  • Grade 1 Akathisia, CTCAE|Grade 1 Akathisia

    mild restlessness or increased motor activity
  • Grade 2 Akathisia, CTCAE|Grade 2 Akathisia

    moderate restlessness or increased motor activity; limiting instrumental adl
  • Grade 3 Akathisia, CTCAE|Grade 3 Akathisia

    severe restlessness or increased motor activity; limiting self care adl
  • Aseptic Meningitis

    inflammation of the membranes surrounding the brain and spinal cord without a bacterial pathogen.
  • Ocular Cicatricial Pemphigoid

    a chronic autoimmune disorder that belongs to the mucous membrane pemphigoid disorders. it is characterized by bilateral scarring and opacification of the conjunctivae. it presents with pain and burning sensation in the eyes and photophobia. it leads to blindness.
  • Benign Mucous Membrane Pemphigoid

    a chronic autoimmune disorder characterized by the development of blisters and ulcers in mucous membranes. it affects most often the gums, eyelids and genital mucosa sites.
  • Erythromelalgia

    a rare disorder characterized by periodic inflammation and blockage of the vessels of the extremities, resulting in skin redness, swelling, and burning pain in the affected sites. it may manifest as a primary disorder caused by mutations of the scn9a gene or as a secondary disorder due to hematologic disorders or medication side effects.
  • Primary Erythermalgia|PERYTHM|Primary Erythromelalgia

    an autosomal dominant condition caused by mutation(s) in the scn9a gene, encoding sodium channel protein type 9 subunit alpha. it is characterized by episodes of recurrent warmth, redness, and burning sensations in the extremities.
  • Primary Erythromelalgia|PERYTHM|Primary Erythermalgia

    an autosomal dominant condition caused by mutation(s) in the scn9a gene, encoding sodium channel protein type 9 subunit alpha. it is characterized by episodes of recurrent warmth, redness, and burning sensations in the extremities.
  • Telogen Effluvium

    a scalp hair loss condition characterized by excessive shedding of hair in the resting phase of growth, usually following a fever or major body stress.
  • Grade 1 Hirsutism, CTCAE|Grade 1 Hirsutism

    in women, increase in length, thickness or density of hair in a male distribution that the patient is able to camouflage by periodic shaving, bleaching, or removal of hair
  • Grade 2 Hirsutism, CTCAE|Grade 2 Hirsutism

    in women, increase in length, thickness or density of hair in a male distribution that requires daily shaving or consistent destructive means of hair removal to camouflage; associated with psychosocial impact
  • Hirsutism

    male-pattern hair growth on a female.
  • Hirsutism, CTCAE|Hirsutism|Hirsutism

    a disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).
  • Acanthosis Nigricans

    a melanotic cutaneous lesion that develops in the axilla and other body folds. it may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.
  • Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome

    a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.
  • Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome

    a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.
  • Hyperpyrexia

    body temperature of 106 degrees fahrenheit (41.1 degrees celsius) or higher.
  • Malignant Hyperthermia Syndrome|Malignant Hyperpyrexia|Malignant Hyperthermia|Malignant Hyperthermia

    a rare disorder characterized by rapid rise of the body temperature, accompanied by rhabdomyolysis and, if untreated, by collapse and death. it occurs in susceptible individuals who receive certain drugs for general anesthesia, gas anesthetics, or succinylcholine. it may be inherited in an autosomal dominant pattern.
  • Bronchospasm

    sudden contraction of the smooth muscles of the bronchial wall.
  • Bronchospasm, CTCAE|Bronchospasm|Bronchospasm

    a disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.
  • Exercise-Induced Bronchospasm|Exercise induced bronchospasm

    sudden contraction of the smooth muscles of the bronchial wall that occurs during or following exercise.
  • Grade 1 Bronchospasm, CTCAE|Grade 1 Bronchospasm

    mild symptoms; intervention not indicated
  • Grade 2 Bronchospasm, CTCAE|Grade 2 Bronchospasm

    symptomatic; medical intervention indicated; limiting instrumental adl
  • Grade 3 Bronchospasm, CTCAE|Grade 3 Bronchospasm

    limiting self care adl; supplemental oxygen indicated
  • Grade 4 Bronchospasm, CTCAE|Grade 4 Bronchospasm

    life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated
  • Grade 5 Bronchospasm, CTCAE|Grade 5 Bronchospasm

    death
  • Toxic Polyneuropathy

    polyneuropathy that is caused by exposure to toxins.
  • Desmoglein-3|130 kDa Pemphigus Vulgaris Antigen|Cadherin Family Member 6|DESMOGLEIN 3|DSG3|Desmoglein 3|PVA

    desmoglein-3 (999 aa, ~108 kda) is encoded by the human dsg3 gene. this protein plays a role in desmosome-mediated cell-cell adhesion.
  • DSG3 Antibody Positive|Anti-DSG3 Antibody Positive|Anti-Desmoglein 3 Antibody Positive|Anti-Desmoglein-3 Antibody Positive|Anti-PVA Antibody Positive|CDHF6 Antibody Positive|Cadherin Family Member 6 Antibody Positive|Desmoglein 3 Antibody Positive|Desmoglein-3 Antibody Positive|PVA Antibody Positive|Pemphigus Vulgaris Antigen Antibody Positive

    an indication that antibodies that recognize desmoglein-3 (dsg3) have been detected in a sample.
  • DSG3 wt Allele|ABOLM|CDHF6|Desmoglein 3 (Pemphigus Vulgaris Antigen) Gene|Desmoglein 3 wt Allele|PVA|Pemphigus Vulgaris Antigen Gene

    human dsg3 wild-type allele is located in the vicinity of 18q12.1 and is approximately 31 kb in length. this allele, which encodes desmoglein-3 protein, is involved in the modulation of cell-cell adhesion.
  • Mucosal-Dominant Pemphigus Vulgaris|Mucosal Dominant Pemphigus Vulgaris|mPV

    a subtype of pemphigus vulgaris in which lesions are predominantly found on mucosal membranes with relative sparing of cutaneous tissues.
  • Pemphigus Vulgaris

    an autoimmune blistering disorder. it is characterized by the presence of painful blisters and erosions in the skin and mucous membranes.
  • Priapism

    persistent and usually painful erection that lasts for at least four hours in the absence of physical or psychological stimulation, which can be caused by hematologic disorders, including sickle cell disease and leukemia, spinal cord injuries, and medications.
  • Acquired Central Hypothyroidism

    central hypothyroidism, the cause of which is not present at birth.
  • Fixed Drug Eruption

    round areas of red-purple reaction in the skin that result after drug exposure; these recur in the same location when the medication is readministered.
  • Onycholysis

    a nail condition characterized by spontaneous separation of a fingernail or toenail from its nail bed.
  • Bullous Pemphigoid

    an autoimmune chronic skin disorder characterized by the presence of large blisters. it usually affects elderly people and tends to subside spontaneously.
  • COL17A1 wt Allele|BA16H23.2|BA16H23.2 (Collagen, Type XVII, Alpha 1 (BP180)) Gene|BP180|BPA-2|BPAG2|Bullous Pemphigoid Antigen 2 (180kD) Gene|Collagen Type XVII Alpha 1 Chain wt Allele|Collagen, Type XVII, Alpha 1 Gene|Collagen, Type XVII, Alpha-1 Gene|ERED|LAD-1

    human col17a1 wild-type allele is located in the vicinity of 10q25.1 and is approximately 55 kb in length. this allele, which encodes collagen alpha-1(xvii) chain protein, is involved in hemidesmosome formation and keratinocyte adhesion. mutation of the gene and immunoreactivity during revertant mosaicism is associated with both generalized atrophic benign and junctional epidermolysis bullosa. mutations in the gene are also associated with epithelial recurrent erosion dystrophy.
  • Collagen Alpha-1(XVII) Chain|180 kDa Bullous Pemphigoid Antigen 2|Alpha 1 Type XVII Collagen|Bullous Pemphigoid Antigen 2|COL17A1|Collagen Type XVII Alpha 1 Chain|Collagen Type XVII Alpha 1 Polypeptide|Type XVII Collagen Alpha-1

    collagen alpha-1(xvii) chain (1497 aa, ~150 kda) is encoded by the human col17a1 gene. this protein plays a role in the attachment of keratinocytes to the basement membrane.
  • Dystonin|230 kDa Bullous Pemphigoid Antigen|230/240 kDa Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1, 230/240kDa|DST|Dystonia Musculorum Protein|Hemidesmosomal Plaque Protein|Trabeculin-Beta

    dystonin (7570 aa, ~860 kda) is encoded by the human dst gene. this protein plays a structural role in cytoskeleton networks.
  • Pulmonary Toxicity

    toxicity that impairs or damages the lung(s). this condition is often caused by the administration of a pharmaceutical agent that causes damage to the lungs.
  • Ototoxicity

    damage to the inner ear as a result of exposure to drugs or chemicals.
  • Phototoxicity Study|PHOTOTOXICITY

    a study of the effect of an agent on the skin or eyes, such that it induces a sensitivity to sunlight or other forms of light.
  • Phototoxicity|phototoxicity

    a nonimmunologic, chemically induced type of photosensitivity.
  • Drug Induced Gingival Hyperplasia

    overgrowth of the gingival tissue caused by phenytoin, cyclosporine a, and calcium channel blockers.
  • Pseudoporphyria

    a drug-induced photodermatosis characterized by skin fragility, erythema, and the appearance of tense bullae, erosions and scarring in the absence of abnormalities in porphyrin metabolism.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances (T50). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Table of Drugs and Chemicals

The code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
Acidifying agent NECT50.901T50.902T50.903T50.904T50.905T50.906
Adjunct, pharmaceuticalT50.901T50.902T50.903T50.904T50.905T50.906
Alkalinizing agents (medicinal)T50.901T50.902T50.903T50.904T50.905T50.906
Alkalizing agent NECT50.901T50.902T50.903T50.904T50.905T50.906
Biological substance NECT50.901T50.902T50.903T50.904T50.905T50.906
Dietetic drug NECT50.901T50.902T50.903T50.904T50.905T50.906
Drug NECT50.901T50.902T50.903T50.904T50.905T50.906
Drug NEC
  »specified NEC
T50.901T50.902T50.903T50.904T50.905T50.906
Elemental dietT50.901T50.902T50.903T50.904T50.905T50.906
Excipients, pharmaceuticalT50.901T50.902T50.903T50.904T50.905T50.906
Headache cures, drugs, powders NECT50.901T50.902T50.903T50.904T50.905T50.906
Lactose (as excipient)T50.901T50.902T50.903T50.904T50.905T50.906
Lipotropic drug NECT50.901T50.902T50.903T50.904T50.905T50.906
Medicament NECT50.901T50.902T50.903T50.904T50.905T50.906
Nutritional supplementT50.901T50.902T50.903T50.904T50.905T50.906
PharmaceuticalT50.901T50.902T50.903T50.904T50.905T50.906
Pharmaceutical
  »adjunct NEC
T50.901T50.902T50.903T50.904T50.905T50.906
Pharmaceutical
  »excipient NEC
T50.901T50.902T50.903T50.904T50.905T50.906
Pharmaceutical
  »sweetener
T50.901T50.902T50.903T50.904T50.905T50.906
Pharmaceutical
  »viscous agent
T50.901T50.902T50.903T50.904T50.905T50.906
SaccharinT50.901T50.902T50.903T50.904T50.905T50.906
Salt substituteT50.901T50.902T50.903T50.904T50.905T50.906
Salt-replacing drugT50.901T50.902T50.903T50.904T50.905T50.906
Sodium-free saltT50.901T50.902T50.903T50.904T50.905T50.906
Soothing syrupT50.901T50.902T50.903T50.904T50.905T50.906
StarchT50.901T50.902T50.903T50.904T50.905T50.906
Stone-dissolving drugT50.901T50.902T50.903T50.904T50.905T50.906
SweetenerT50.901T50.902T50.903T50.904T50.905T50.906
Tablets [See Also: specified substance]T50.901T50.902T50.903T50.904T50.905T50.906
Tonic NECT50.901T50.902T50.903T50.904T50.905T50.906
Viscous agentT50.901T50.902T50.903T50.904T50.905T50.906

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.